Search clinical trials for: Empagliflozin Tablets

Total 7444 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
University of California, San Diego
Juvenile Diabetes Research Foundation

Completed

Dapagliflozin Effects on Hypoglycemia

Type1 Diabetes Mellitus

United States
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy (ESPRIT)

Ischemic Stroke, Acute

China
Samsung Medical Center

Recruiting

SGLT2 Inhibitor for Severe Tricuspid Regurgitation (Reduction-TR)

Tricuspid Regurgitation

Korea, Republic of
Damanhour University

Completed

Ivabradine in Patients With Congestive Heart Failure

Congestive Heart Failure

Egypt
Damanhour University
Menoufia University

Unknown

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Cardiomyopathies | Diabete Type 2 | Heart Failure With Reduced Ejection Fraction (HFrEF)
University Hospital, Basel, Switzerland

Completed

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study (DIVE)

Inappropriate ADH Syndrome

Switzerland
University of Virginia

Recruiting

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease (SMILE)

Myocardial Ischemia

United States
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Tan Tock Seng Hospital

Recruiting

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes (DMVascular)

Diabetes

Singapore
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States
Bio-innova Co., Ltd

Not yet recruiting

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Healthy Subjects
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Stallergenes Greer

Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Asthma | House Dust Mite Allergy

France, Germany, Poland
University of Pennsylvania

Recruiting

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Heart Failure With Preserved Ejection Fraction

United States
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Healthy

Germany
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
The University of Hong Kong
Research Grant Council

Recruiting

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

Cirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 Inhibitors

Hong Kong
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
University Hospital, Basel, Switzerland

Active, not recruiting

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (Hypo-PrEA)

Postprandial Hypoglycemia

Switzerland
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Anita Saraf
The Pittsburgh Foundation

Not yet recruiting

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease (EmpaCHD)

Heart Failure | Adult Congenital Heart Disease

United States
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Healthy

Germany
Caroline M Kistorp
Rigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart Foundation

Completed

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk (SIMPLE)

Type2 Diabetes Mellitus

Denmark
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...

Recruiting

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Type2 Diabetes | Heart Failure With Preserved Ejection Fraction

United States
Chong Kun Dang Pharmaceutical

Unknown

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Diabetes Mellitus, Type II

Korea, Republic of
LG Chem

Not yet recruiting

Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50/10 mg

Healthy Volunteers
University of Campinas, Brazil
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Hypertension | Obesity | Diabetes Mellitus, Type 2 | Blood Pressure | Vascular Stiffness | Cardiac Hypertrophy | Microalbuminuria

Brazil
Boehringer Ingelheim
Eli Lilly and Company

Completed

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion (CRYSTAL)

Acute Ischemic Stroke | Large Vessel Occlusion | Reperfusion

China
University of Diyala

Completed

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Type 2 Diabetes

Iraq
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
Nanoform Finland Plc

Completed

PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects

Pain

United Kingdom
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
RH Nanopharmaceuticals
Center for Bioequivalence Studies and Clinical Research

Completed

Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers

Pharmacokinetics | Tolerability | Safety

Pakistan
EMS

Not yet recruiting

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus (PIEMONTE)

Type II Diabetes
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 (MERCURI-2)

Acute Kidney Injury | Cardiac Surgery | Sodium-Glucose Transporter 2 Inhibitor

Netherlands
Boehringer Ingelheim

Completed

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Healthy

Germany
Aveiro University

Completed

Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders

Speech Disorders

Portugal

Search clinical trials for: Empagliflozin Tablets

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations